Sichuan Biokin Pharmaceutical (688506.SH): Clinical trial of injectable BL-M24D1 (ADC) drug approved.
Baili Tianheng(688506.SH) announcement, the company recently received the official National Medical Products Administration(NMPA)...
Sichuan Biokin Pharmaceutical (688506.SH) announced that the company has recently received the official approval from the National Medical Products Administration (NMPA) for the issuance of the "Drug Clinical Trial Approval Notice" for the company's independently developed innovative biopharmaceutical injection BL-M24D1 (ADC) for clinical trials.
BL-M24D1 is an ADC drug independently developed by the company, which is coupled with a new generation toxin. It comes from the same small molecule technology platform as BL-B16D1 and BL-M17D1, and shares the same "linker + toxin" platform. Its indications are recurrent or refractory hematologic malignancies and advanced solid tumors.
Related Articles

Program lineup unprecedented, but profits fell victim to an "ambush"! Netflix (NFLX.US) misses performance expectations due to a Brazilian tax case, causing after-hours stock prices to plummet.

FSM HOLDINGS (01721): Li Thet resigns as executive director.

Soochow: Energy storage in September and October exceeded expectations, wind power bidding improved, and the photovoltaic anti-dumping investigation continued to advance.
Program lineup unprecedented, but profits fell victim to an "ambush"! Netflix (NFLX.US) misses performance expectations due to a Brazilian tax case, causing after-hours stock prices to plummet.

FSM HOLDINGS (01721): Li Thet resigns as executive director.

Soochow: Energy storage in September and October exceeded expectations, wind power bidding improved, and the photovoltaic anti-dumping investigation continued to advance.

RECOMMEND

Why European Automakers Are Opposing Dutch Sanctions
20/10/2025

Domestic Commercial Rockets Enter Batch Launch Era: Behind the Scenes a Sixfold Cost Gap and Reusability as the Key Breakthrough
20/10/2025

Multiple Positive Catalysts Lift Tech Stocks; UBS Elevates China Tech to Most Attractive, Citing AI as Core Rationale
20/10/2025